Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD-209-1C (Addpharma, Inc.)
- Development stage
- Unknown
- Lead developer
- Addpharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AD-209-1C is a specific dose variant of the AD-209 triple combination therapy developed by Addpharma Inc. for the treatment of essential hypertension. It is a fixed-dose combination containing three active ingredients: amlodipine (a dihydropyridine calcium channel blocker), telmisartan (an angiotensin II receptor blocker), and chlorthalidone (a thiazide-like diuretic). Classified as an incrementally modified drug (IMD) in South Korea, AD-209-1C is designed to provide comprehensive blood pressure control by targeting multiple physiological pathways simultaneously. The drug is administered orally as a film-coated tablet. Following the completion of Phase 2 clinical trials, the AD-209 program has progressed into Phase 3 development for patients with essential hypertension who require intensive blood pressure management.
- Other names
- amlodipine + telmisartan + chlorthalidone
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR1 (Angiotensin II Type-1 receptor)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)
Beyond the preview
Go deeper on AD-209-1C (Addpharma, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD-209-1C (Addpharma, Inc.).